CN103182059A - Traditional Chinese medicine composition for treating chronic gastritis, and application thereof - Google Patents
Traditional Chinese medicine composition for treating chronic gastritis, and application thereof Download PDFInfo
- Publication number
- CN103182059A CN103182059A CN2013100849697A CN201310084969A CN103182059A CN 103182059 A CN103182059 A CN 103182059A CN 2013100849697 A CN2013100849697 A CN 2013100849697A CN 201310084969 A CN201310084969 A CN 201310084969A CN 103182059 A CN103182059 A CN 103182059A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- rhizoma
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for treating chronic gastritis, which comprises the following raw material medicine: radix codonopsitis, astragalus root, rhizoma atractylodis macrocephalae stir-fried with bran, Chinese date, rehmannia root, Chinese angelica root, moutan bark, chuanxiong rhizome, zedoary, trichosanthes root and dandehon herb. The invention also provides an application of the traditional Chinese medicine composition. The traditional Chinese medicine composition has the effects of strengthening the spleen and stomach, nourishing yin, clearing away heat, activating qi and resolving masses, conforms to the principle of monarch, minister, assistant and guide of traditional Chinese medicine based on the compatibility of the whole formula, and has the effect of preventing and treating chronic gastritis; and the clinical studies show that the traditional Chinese medicine composition can obviously improve various clinical symptoms of patients such as epigastric pain, abdominal distention, belching and acid regurgitation, is suitable for long-term use, is a safe and effective traditional Chinese medicine composition for treating chronic gastritis, and has a good application prospect.
Description
Technical field
The present invention relates to technical field of Chinese medicines, specifically, is a kind of Chinese medicine composition and application thereof for the treatment of chronic gastritis.
Background technology
Chronic gastritis (chronicgastritis) is the gastric mucosa chronic inflammatory disease that is caused by the various causes of disease.According to histopathology change and pathological changes at the distribution position of stomach, in conjunction with the possible cause of disease, chronic gastritis is divided into non-atrophic (in the past claiming shallow non-atrophic), atrophic (atrophic) and specific type (special forms) three major types.Chronic non-atrophic gastritis refers to see the chronic gastritis based on the chronic inflammatory cell infiltration of lymphocyte and plasma cell without the change of gastric mucosa atrophic, gastric mucosa layer.According to the position that inflammation distributes, can be further divided into gastric antrum gastritis, body of stomach gastritis and full gastritis.Gastric antrum gastritis at first takes place in helicobacter pylori infections, is full gastritis to the stomach proximal spread gradually then, and full gastritis whether develop to reach and develops speed and have tangible individual variation and regional difference; The chronic gastritis that autoimmune causes mainly shows as body of stomach gastritis.Chronic atrophic gastritis refers to that the chronic gastritis that atrophic changes has taken place gastric mucosa.Chronic atrophic gastritis is called for short (CAG), can be further divided into many kitchen ranges atrophic (multifocal atrophic) gastritis and autoimmunity (autoimmune) gastritis two big classes again.The former is the distribution of many kitchen ranges property at gastric at the atrophic change, and based on gastric antrum, the chronic non-atrophic gastritis how to be caused by helicobacter pylori infections develop; Latter's atrophy change mainly is positioned at body of stomach, and the body of stomach gastritis how to be caused by autoimmune develop.Specific type gastritis kind is a lot, and is due to the different causes of disease, more rare clinically.
Lot of documents report prompting in recent years adopts Chinese medicine prevention CAG in the clinical symptoms of improving the patient and sign, improves pathological change aspects such as intestinal epithelial metaplasia, atrophy and has remarkable advantages.
Summary of the invention
The objective of the invention is at deficiency of the prior art, a kind of Chinese medicine composition for the treatment of chronic gastritis is provided.
One purpose more of the present invention is that the Chinese medicine composition of second kind for the treatment of chronic gastritis is provided.
Another purpose of the present invention is that a kind of application for the treatment of the Chinese medicine composition of chronic gastritis is provided.
For achieving the above object, the technical scheme that the present invention takes is: a kind of Chinese medicine composition for the treatment of chronic gastritis, described Chinese medicine composition is mainly made by following bulk drugs: Radix Codonopsis 30-35 part, Radix Astragali 25-30 part, Rhizoma Atractylodis Macrocephalae (parched with bran) 15-25 part, Fructus Jujubae 30-35 part, Radix Rehmanniae 25-30 part, Radix Angelicae Sinensis 25-30 part, Cortex Moutan 25-30 part, Rhizoma Chuanxiong 25-30 part, Rhizoma Curcumae 25-30 part, Radix Trichosanthis 25-30 part, Herba Taraxaci 20-25 part.
Described Chinese medicine composition is mainly made by following bulk drugs: Radix Codonopsis 33-34 part, Radix Astragali 26-27 part, Rhizoma Atractylodis Macrocephalae (parched with bran) 19-21 part, Fructus Jujubae 33-34 part, Radix Rehmanniae 26-27 part, Radix Angelicae Sinensis 26-27 part, Cortex Moutan 26-27 part, Rhizoma Chuanxiong 26-27 part, Rhizoma Curcumae 26-27 part, Radix Trichosanthis 26-27 part, Herba Taraxaci 23-24 part.
Described Chinese medicine composition is mainly made by following bulk drugs: 33.3 parts of Radix Codonopsis, 26.7 parts of the Radixs Astragali, 20 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 33.3 parts in Fructus Jujubae, 26.7 parts of Radix Rehmanniae, 26.7 parts of Radix Angelicae Sinensis, 26.7 parts of Cortex Moutans, 26.7 parts of Rhizoma Chuanxiongs, 26.7 parts of Rhizoma Curcumae, 26.7 parts of Radix Trichosanthis, 23.3 parts of Herba Taraxacis.
For realizing above-mentioned second purpose, the technical scheme that the present invention takes is: a kind of Chinese medicine composition for the treatment of chronic gastritis, and described Chinese medicine composition is mainly made by following bulk drugs: Herba Pogostemonis stalk 15-25 part, Caulis Perillae 15-25 part, Rhizoma Atractylodis Macrocephalae (parched with bran) 15-25 part, stir-baked Fructus Aurantii in bran 15-25 part, Semen Vignae Cylindricae KOUREN 5-10 part, Fructus Citri Sarcodactylis 15-25 part, Fructus Mume 5-15 part processed, Rhizoma Zingiberis Recens 10-15 part, Fructus Jujubae 30-35 part, Radix Glycyrrhizae 10-15 part, Radix Astragali 25-30 part, Radix Rehmanniae 25-30 part, Cortex Moutan 25-30 part, Radix Trichosanthis 25-30 part, Herba Taraxaci 20-25 part, Radix Angelicae Sinensis 25-30 part, Rhizoma Chuanxiong 25-30 part, Rhizoma Curcumae 25-30 part, Fructus Lycii 25-30 part, Rhizoma Coptidis 1-4 part, Radix Codonopsis 30-35 part.
Described Chinese medicine composition is mainly made by following bulk drugs: Herba Pogostemonis stalk 17-23 part, Caulis Perillae 17-23 part, Rhizoma Atractylodis Macrocephalae (parched with bran) 17-23 part, stir-baked Fructus Aurantii in bran 17-23 part, Semen Vignae Cylindricae KOUREN 6-7 part, Fructus Citri Sarcodactylis 17-23 part, Fructus Mume 7-13 part processed, Rhizoma Zingiberis Recens 13-14 part, Fructus Jujubae 33-34 part, Radix Glycyrrhizae 13-14 part, Radix Astragali 26-27 part, Radix Rehmanniae 26-27 part, Cortex Moutan 26-27 part, Radix Trichosanthis 26-27 part, Herba Taraxaci 23-24 part, Radix Angelicae Sinensis 26-27 part, Rhizoma Chuanxiong 26-27 part, Rhizoma Curcumae 26-27 part, Fructus Lycii 26-27 part, Rhizoma Coptidis 2-3 part, Radix Codonopsis 33-34 part.
Described Chinese medicine composition is mainly made by following bulk drugs: 20 parts on Herba Pogostemonis stalk, 20 parts of Caulis Perillaes, 20 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 20 parts of stir-baked Fructus Aurantii in bran, 6.7 parts of Semen Vignae Cylindricae KOUREN, 20 parts of Fructus Citri Sarcodactylis, 10 parts of Fructus Mumes processed, 13.3 parts in Rhizoma Zingiberis Recens, 33.3 parts in Fructus Jujubae, 13.3 parts in Radix Glycyrrhizae, 26.7 parts of the Radixs Astragali, 26.7 parts of Radix Rehmanniae, 26.7 parts of Cortex Moutans, 26.7 parts of Radix Trichosanthis, 23.3 parts of Herba Taraxacis, 26.7 parts of Radix Angelicae Sinensis, 26.7 parts of Rhizoma Chuanxiongs, 26.7 parts of Rhizoma Curcumae, 26.7 parts of Fructus Lycii, 2.3 parts of Rhizoma Coptidis, 33.3 parts of Radix Codonopsis.
For realizing above-mentioned the 3rd purpose, the technical scheme that the present invention takes is: the application of described Chinese medicine composition in the medicine of preparation treatment chronic gastritis.
Described chronic gastritis is chronic atrophic gastritis.
The invention has the advantages that:
Chinese medicine composition of the present invention has invigorating the spleen and regulating the stomach, replenishing YIN and removing heat, the effect of promoting QI to circulate and dispersing the agglomeration of the pathogens, full side's compatibility meets Chinese medicine " monarch " principle, have the effect of the chronic gastritis of preventing and treating, clinical research shows: Chinese medicine composition of the present invention can significantly improve clinical symptoms such as patient's gastric abscess, abdominal distention and belch pantothenic acid, is suitable for taking for a long time, be a kind of Chinese medicine composition for the treatment of chronic gastritis safely and effectively, have a good application prospect.
The specific embodiment
Below in conjunction with embodiment the specific embodiment provided by the invention is elaborated.
The invention provides a kind of Chinese medicine composition one for the treatment of chronic gastritis, mainly made by following bulk drugs: Radix Codonopsis 30-35 part, Radix Astragali 25-30 part, Rhizoma Atractylodis Macrocephalae (parched with bran) 15-25 part, Fructus Jujubae 30-35 part, Radix Rehmanniae 25-30 part, Radix Angelicae Sinensis 25-30 part, Cortex Moutan 25-30 part, Rhizoma Chuanxiong 25-30 part, Rhizoma Curcumae 25-30 part, Radix Trichosanthis 25-30 part, Herba Taraxaci 20-25 part.
Embodiment 1 Chinese medicine composition one
30 parts of Radix Codonopsis, 30 parts of the Radixs Astragali, 15 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 35 parts in Fructus Jujubae, 25 parts of Radix Rehmanniae, 30 parts of Radix Angelicae Sinensis, 25 parts of Cortex Moutans, 30 parts of Rhizoma Chuanxiongs, 25 parts of Rhizoma Curcumae, 30 parts of Radix Trichosanthis, 20 parts of Herba Taraxacis.
Embodiment 2 Chinese medicine compositions one
31 parts of Radix Codonopsis, 29 parts of the Radixs Astragali, 16 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 34 parts in Fructus Jujubae, 26 parts of Radix Rehmanniae, 29 parts of Radix Angelicae Sinensis, 26 parts of Cortex Moutans, 29 parts of Rhizoma Chuanxiongs, 26 parts of Rhizoma Curcumae, 29 parts of Radix Trichosanthis, 21 parts of Herba Taraxacis.
Embodiment 3 Chinese medicine compositions one
32 parts of Radix Codonopsis, 28 parts of the Radixs Astragali, 17 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 33 parts in Fructus Jujubae, 27 parts of Radix Rehmanniae, 28 parts of Radix Angelicae Sinensis, 27 parts of Cortex Moutans, 28 parts of Rhizoma Chuanxiongs, 27 parts of Rhizoma Curcumae, 28 parts of Radix Trichosanthis, 22 parts of Herba Taraxacis.
Embodiment 4 Chinese medicine compositions one
33 parts of Radix Codonopsis, 27 parts of the Radixs Astragali, 18 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 32 parts in Fructus Jujubae, 28 parts of Radix Rehmanniae, 27 parts of Radix Angelicae Sinensis, 28 parts of Cortex Moutans, 27 parts of Rhizoma Chuanxiongs, 28 parts of Rhizoma Curcumae, 27 parts of Radix Trichosanthis, 23 parts of Herba Taraxacis.
Embodiment 5 Chinese medicine compositions one
34 parts of Radix Codonopsis, 26 parts of the Radixs Astragali, 19 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 31 parts in Fructus Jujubae, 29 parts of Radix Rehmanniae, 26 parts of Radix Angelicae Sinensis, 29 parts of Cortex Moutans, 26 parts of Rhizoma Chuanxiongs, 29 parts of Rhizoma Curcumae, 26 parts of Radix Trichosanthis, 24 parts of Herba Taraxacis.
Embodiment 6 Chinese medicine compositions one
35 parts of Radix Codonopsis, 25 parts of the Radixs Astragali, 20 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 30 parts in Fructus Jujubae, 30 parts of Radix Rehmanniae, 25 parts of Radix Angelicae Sinensis, 30 parts of Cortex Moutans, 25 parts of Rhizoma Chuanxiongs, 30 parts of Rhizoma Curcumae, 25 parts of Radix Trichosanthis, 25 parts of Herba Taraxacis.
Embodiment 7 Chinese medicine compositions one
34 parts of Radix Codonopsis, 26.2 parts of the Radixs Astragali, 21 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 34 parts in Fructus Jujubae, 27 parts of Radix Rehmanniae, 26.2 parts of Radix Angelicae Sinensis, 26.8 parts of Cortex Moutans, 26.2 parts of Rhizoma Chuanxiongs, 26.2 parts of Rhizoma Curcumae, 26.8 parts of Radix Trichosanthis, 23.2 parts of Herba Taraxacis.
Embodiment 8 Chinese medicine compositions one
33 parts of Radix Codonopsis, 26.4 parts of the Radixs Astragali, 22 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 33 parts in Fructus Jujubae, 26.8 parts of Radix Rehmanniae, 26.4 parts of Radix Angelicae Sinensis, 26.6 parts of Cortex Moutans, 26.4 parts of Rhizoma Chuanxiongs, 26.4 parts of Rhizoma Curcumae, 26.6 parts of Radix Trichosanthis, 23.4 parts of Herba Taraxacis.
Embodiment 9 Chinese medicine compositions one
33.5 parts of Radix Codonopsis, 26.6 parts of the Radixs Astragali, 23 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 33.5 parts in Fructus Jujubae, 26.6 parts of Radix Rehmanniae, 26.6 parts of Radix Angelicae Sinensis, 26.4 parts of Cortex Moutans, 26.6 parts of Rhizoma Chuanxiongs, 26.6 parts of Rhizoma Curcumae, 26.4 parts of Radix Trichosanthis, 23.6 parts of Herba Taraxacis.
Embodiment 10 Chinese medicine compositions one
33.7 parts of Radix Codonopsis, 26.8 parts of the Radixs Astragali, 24 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 33.7 parts in Fructus Jujubae, 26.4 parts of Radix Rehmanniae, 26.8 parts of Radix Angelicae Sinensis, 26.2 parts of Cortex Moutans, 26.8 parts of Rhizoma Chuanxiongs, 26.8 parts of Rhizoma Curcumae, 26.2 parts of Radix Trichosanthis, 23.8 parts of Herba Taraxacis.
Embodiment 11 Chinese medicine compositions one
33.9 parts of Radix Codonopsis, 27 parts of the Radixs Astragali, 25 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 33.9 parts in Fructus Jujubae, 26.2 parts of Radix Rehmanniae, 27 parts of Radix Angelicae Sinensis, 26 parts of Cortex Moutans, 27 parts of Rhizoma Chuanxiongs, 27 parts of Rhizoma Curcumae, 26 parts of Radix Trichosanthis, 24 parts of Herba Taraxacis.
Embodiment 12 Chinese medicine compositions one
33.3 parts of Radix Codonopsis, 26.7 parts of the Radixs Astragali, 20 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 33.3 parts in Fructus Jujubae, 26.7 parts of Radix Rehmanniae, 26.7 parts of Radix Angelicae Sinensis, 26.7 parts of Cortex Moutans, 26.7 parts of Rhizoma Chuanxiongs, 26.7 parts of Rhizoma Curcumae, 26.7 parts of Radix Trichosanthis, 23.3 parts of Herba Taraxacis.
The present invention also provides a kind of Chinese medicine composition two for the treatment of chronic gastritis, is mainly made by following bulk drugs: Herba Pogostemonis stalk 15-25 part, Caulis Perillae 15-25 part, Rhizoma Atractylodis Macrocephalae (parched with bran) 15-25 part, stir-baked Fructus Aurantii in bran 15-25 part, Semen Vignae Cylindricae KOUREN 5-10 part, Fructus Citri Sarcodactylis 15-25 part, Fructus Mume 5-15 part processed, Rhizoma Zingiberis Recens 10-15 part, Fructus Jujubae 30-35 part, Radix Glycyrrhizae 10-15 part, Radix Astragali 25-30 part, Radix Rehmanniae 25-30 part, Cortex Moutan 25-30 part, Radix Trichosanthis 25-30 part, Herba Taraxaci 20-25 part, Radix Angelicae Sinensis 25-30 part, Rhizoma Chuanxiong 25-30 part, Rhizoma Curcumae 25-30 part, Fructus Lycii 25-30 part, Rhizoma Coptidis 1-4 part, Radix Codonopsis 30-35 part.
Embodiment 13 Chinese medicine compositions two
30 parts of Radix Codonopsis, 30 parts of the Radixs Astragali, 15 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 35 parts in Fructus Jujubae, 25 parts of Radix Rehmanniae, 30 parts of Radix Angelicae Sinensis, 25 parts of Cortex Moutans, 30 parts of Rhizoma Chuanxiongs, 25 parts of Rhizoma Curcumae, 30 parts of Radix Trichosanthis, 20 parts of Herba Taraxacis, 15 parts on Herba Pogostemonis stalk, 25 parts of Caulis Perillaes, 15 parts of stir-baked Fructus Aurantii in bran, 10 parts of Semen Vignae Cylindricae KOUREN, 15 parts of Fructus Citri Sarcodactylis, 15 parts of Fructus Mumes processed, 10 parts in Rhizoma Zingiberis Recens, 10 parts in Radix Glycyrrhizae, 25 parts of Fructus Lycii, 1 part of Rhizoma Coptidis.
Embodiment 14 Chinese medicine compositions two
31 parts of Radix Codonopsis, 29 parts of the Radixs Astragali, 16 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 34 parts in Fructus Jujubae, 26 parts of Radix Rehmanniae, 29 parts of Radix Angelicae Sinensis, 26 parts of Cortex Moutans, 29 parts of Rhizoma Chuanxiongs, 26 parts of Rhizoma Curcumae, 29 parts of Radix Trichosanthis, 21 parts of Herba Taraxacis, 16 parts on Herba Pogostemonis stalk, 24 parts of Caulis Perillaes, 16 parts of stir-baked Fructus Aurantii in bran, 9 parts of Semen Vignae Cylindricae KOUREN, 16 parts of Fructus Citri Sarcodactylis, 14 parts of Fructus Mumes processed, 11 parts in Rhizoma Zingiberis Recens, 11 parts in Radix Glycyrrhizae, 26 parts of Fructus Lycii, 2 parts of Rhizoma Coptidis.
Embodiment 15 Chinese medicine compositions two
32 parts of Radix Codonopsis, 28 parts of the Radixs Astragali, 17 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 33 parts in Fructus Jujubae, 27 parts of Radix Rehmanniae, 28 parts of Radix Angelicae Sinensis, 27 parts of Cortex Moutans, 28 parts of Rhizoma Chuanxiongs, 27 parts of Rhizoma Curcumae, 28 parts of Radix Trichosanthis, 22 parts of Herba Taraxacis, 17 parts on Herba Pogostemonis stalk, 23 parts of Caulis Perillaes, 17 parts of stir-baked Fructus Aurantii in bran, 8 parts of Semen Vignae Cylindricae KOUREN, 17 parts of Fructus Citri Sarcodactylis, 13 parts of Fructus Mumes processed, 12 parts in Rhizoma Zingiberis Recens, 12 parts in Radix Glycyrrhizae, 27 parts of Fructus Lycii, 3 parts of Rhizoma Coptidis.
Embodiment 16 Chinese medicine compositions two
33 parts of Radix Codonopsis, 27 parts of the Radixs Astragali, 18 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 32 parts in Fructus Jujubae, 28 parts of Radix Rehmanniae, 27 parts of Radix Angelicae Sinensis, 28 parts of Cortex Moutans, 27 parts of Rhizoma Chuanxiongs, 28 parts of Rhizoma Curcumae, 27 parts of Radix Trichosanthis, 23 parts of Herba Taraxacis, 18 parts on Herba Pogostemonis stalk, 22 parts of Caulis Perillaes, 18 parts of stir-baked Fructus Aurantii in bran, 7 parts of Semen Vignae Cylindricae KOUREN, 18 parts of Fructus Citri Sarcodactylis, 12 parts of Fructus Mumes processed, 13 parts in Rhizoma Zingiberis Recens, 13 parts in Radix Glycyrrhizae, 28 parts of Fructus Lycii, 4 parts of Rhizoma Coptidis.
Embodiment 17 Chinese medicine compositions two
34 parts of Radix Codonopsis, 26 parts of the Radixs Astragali, 19 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 31 parts in Fructus Jujubae, 29 parts of Radix Rehmanniae, 26 parts of Radix Angelicae Sinensis, 29 parts of Cortex Moutans, 26 parts of Rhizoma Chuanxiongs, 29 parts of Rhizoma Curcumae, 26 parts of Radix Trichosanthis, 24 parts of Herba Taraxacis, 19 parts on Herba Pogostemonis stalk, 21 parts of Caulis Perillaes, 19 parts of stir-baked Fructus Aurantii in bran, 6 parts of Semen Vignae Cylindricae KOUREN, 19 parts of Fructus Citri Sarcodactylis, 11 parts of Fructus Mumes processed, 14 parts in Rhizoma Zingiberis Recens, 14 parts in Radix Glycyrrhizae, 29 parts of Fructus Lycii, 2.2 parts of Rhizoma Coptidis.
Embodiment 18 Chinese medicine compositions two
35 parts of Radix Codonopsis, 25 parts of the Radixs Astragali, 20 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 30 parts in Fructus Jujubae, 30 parts of Radix Rehmanniae, 25 parts of Radix Angelicae Sinensis, 30 parts of Cortex Moutans, 25 parts of Rhizoma Chuanxiongs, 30 parts of Rhizoma Curcumae, 25 parts of Radix Trichosanthis, 25 parts of Herba Taraxacis, 20 parts on Herba Pogostemonis stalk, 20 parts of Caulis Perillaes, 20 parts of stir-baked Fructus Aurantii in bran, 5 parts of Semen Vignae Cylindricae KOUREN, 20 parts of Fructus Citri Sarcodactylis, 10 parts of Fructus Mumes processed, 15 parts in Rhizoma Zingiberis Recens, 15 parts in Radix Glycyrrhizae, 30 parts of Fructus Lycii, 2.3 parts of Rhizoma Coptidis.
Embodiment 19 Chinese medicine compositions two
34 parts of Radix Codonopsis, 26.2 parts of the Radixs Astragali, 21 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 34 parts in Fructus Jujubae, 27 parts of Radix Rehmanniae, 26.2 parts of Radix Angelicae Sinensis, 26.8 parts of Cortex Moutans, 26.2 parts of Rhizoma Chuanxiongs, 26.2 parts of Rhizoma Curcumae, 26.8 parts of Radix Trichosanthis, 23.2 parts of Herba Taraxacis, 21 parts on Herba Pogostemonis stalk, 19 parts of Caulis Perillaes, 21 parts of stir-baked Fructus Aurantii in bran, 6.2 parts of Semen Vignae Cylindricae KOUREN, 21 parts of Fructus Citri Sarcodactylis, 9 parts of Fructus Mumes processed, 13.2 parts in Rhizoma Zingiberis Recens, 13.2 parts in Radix Glycyrrhizae, 26.2 parts of Fructus Lycii, 2.4 parts of Rhizoma Coptidis.
Embodiment 20 Chinese medicine compositions two
33 parts of Radix Codonopsis, 26.4 parts of the Radixs Astragali, 22 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 33 parts in Fructus Jujubae, 26.8 parts of Radix Rehmanniae, 26.4 parts of Radix Angelicae Sinensis, 26.6 parts of Cortex Moutans, 26.4 parts of Rhizoma Chuanxiongs, 26.4 parts of Rhizoma Curcumae, 26.6 parts of Radix Trichosanthis, 23.4 parts of Herba Taraxacis, 22 parts on Herba Pogostemonis stalk, 18 parts of Caulis Perillaes, 22 parts of stir-baked Fructus Aurantii in bran, 6.4 parts of Semen Vignae Cylindricae KOUREN, 22 parts of Fructus Citri Sarcodactylis, 8 parts of Fructus Mumes processed, 13.4 parts in Rhizoma Zingiberis Recens, 13.4 parts in Radix Glycyrrhizae, 26.4 parts of Fructus Lycii, 2.6 parts of Rhizoma Coptidis.
Embodiment 21 Chinese medicine compositions two
33.5 parts of Radix Codonopsis, 26.6 parts of the Radixs Astragali, 23 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 33.5 parts in Fructus Jujubae, 26.6 parts of Radix Rehmanniae, 26.6 parts of Radix Angelicae Sinensis, 26.4 parts of Cortex Moutans, 26.6 parts of Rhizoma Chuanxiongs, 26.6 parts of Rhizoma Curcumae, 26.4 parts of Radix Trichosanthis, 23.6 parts of Herba Taraxacis, 23 parts on Herba Pogostemonis stalk, 17 parts of Caulis Perillaes, 23 parts of stir-baked Fructus Aurantii in bran, 6.6 parts of Semen Vignae Cylindricae KOUREN, 23 parts of Fructus Citri Sarcodactylis, 7 parts of Fructus Mumes processed, 13.6 parts in Rhizoma Zingiberis Recens, 13.6 parts in Radix Glycyrrhizae, 26.6 parts of Fructus Lycii, 2.8 parts of Rhizoma Coptidis.
Embodiment 22 Chinese medicine compositions two
33.7 parts of Radix Codonopsis, 26.8 parts of the Radixs Astragali, 24 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 33.7 parts in Fructus Jujubae, 26.4 parts of Radix Rehmanniae, 26.8 parts of Radix Angelicae Sinensis, 26.2 parts of Cortex Moutans, 26.8 parts of Rhizoma Chuanxiongs, 26.8 parts of Rhizoma Curcumae, 26.2 parts of Radix Trichosanthis, 23.8 parts of Herba Taraxacis, 24 parts on Herba Pogostemonis stalk, 16 parts of Caulis Perillaes, 24 parts of stir-baked Fructus Aurantii in bran, 6.8 parts of Semen Vignae Cylindricae KOUREN, 24 parts of Fructus Citri Sarcodactylis, 6 parts of Fructus Mumes processed, 13.8 parts in Rhizoma Zingiberis Recens, 13.8 parts in Radix Glycyrrhizae, 26.8 parts of Fructus Lycii, 2.5 parts of Rhizoma Coptidis.
Embodiment 23 Chinese medicine compositions two
33.9 parts of Radix Codonopsis, 27 parts of the Radixs Astragali, 25 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 33.9 parts in Fructus Jujubae, 26.2 parts of Radix Rehmanniae, 27 parts of Radix Angelicae Sinensis, 26 parts of Cortex Moutans, 27 parts of Rhizoma Chuanxiongs, 27 parts of Rhizoma Curcumae, 26 parts of Radix Trichosanthis, 24 parts of Herba Taraxacis, 25 parts on Herba Pogostemonis stalk, 15 parts of Caulis Perillaes, 25 parts of stir-baked Fructus Aurantii in bran, 7 parts of Semen Vignae Cylindricae KOUREN, 25 parts of Fructus Citri Sarcodactylis, 5 parts of Fructus Mumes processed, 14 parts in Rhizoma Zingiberis Recens, 14 parts in Radix Glycyrrhizae, 27 parts of Fructus Lycii, 3 parts of Rhizoma Coptidis.
Embodiment 24 Chinese medicine compositions two
33.3 parts of Radix Codonopsis, 26.7 parts of the Radixs Astragali, 20 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 33.3 parts in Fructus Jujubae, 26.7 parts of Radix Rehmanniae, 26.7 parts of Radix Angelicae Sinensis, 26.7 parts of Cortex Moutans, 26.7 parts of Rhizoma Chuanxiongs, 26.7 parts of Rhizoma Curcumae, 26.7 parts of Radix Trichosanthis, 23.3 parts of Herba Taraxacis, 20 parts on Herba Pogostemonis stalk, 20 parts of Caulis Perillaes, 20 parts of stir-baked Fructus Aurantii in bran, 6.7 parts of Semen Vignae Cylindricae KOUREN, 20 parts of Fructus Citri Sarcodactylis, 10 parts of Fructus Mumes processed, 13.3 parts in Rhizoma Zingiberis Recens, 13.3 parts in Radix Glycyrrhizae, 26.7 parts of Fructus Lycii, 2.3 parts of Rhizoma Coptidis.
The preparation of embodiment 25 Chinese medicine composition decoctions
Adopt the manufacture method of Chinese medicine decoction routine, namely get the arbitrary described Chinese medicine composition of embodiment 1-24 and decoct with water into decoction.
The preparation of embodiment 26 Chinese medicine composition tablets/capsules
Get the arbitrary described Chinese medicine composition of embodiment 1-24, add 6-10 times of water gaging, decocted 1-3 hour, leach medicine juice.Add 6-10 times of water gaging again, decocted 0.5-2 hour, leach medicine juice, merge the secondary decocting liquid, leave standstill, the leaching supernatant concentrates, and puts coldly, adds concentrated solution 2-3 and doubly measures ethanol, stirs precipitation and spends the night.Get supernatant, be concentrated into thick extractum; Add pharmaceutical aids, vacuum drying is pulverized and is granulated, and is pressed into tablet or fills encapsulated.
The preparation of embodiment 27 Chinese medicine composition composition granules
Get the arbitrary described Chinese medicine composition of embodiment 1-24, add 10 times of water gagings, decocted 2 hours, leach medicine juice.Add 8 times of water gagings again, decocted 1 hour, leach medicine juice, merge the secondary decocting liquid, leave standstill, the leaching supernatant concentrates, and puts coldly, adds 2 times of amounts of concentrated solution ethanol, stirs precipitation and spends the night.Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids, granulate, drying, granulate gets the 20g granule, packing 10g/ bag.
The preparation of embodiment 28 Chinese medicine composition mixture/oral liquid/syrups
Get the arbitrary described Chinese medicine composition of embodiment 1-24, add 10 times of water gagings, decocted 2 hours, leach medicine juice.Add 8 times of water gagings again, decocted 1 hour, leach medicine juice, merge the secondary decocting liquid, leave standstill, the leaching supernatant concentrates, and puts coldly, adds 2 times of amounts of concentrated solution ethanol, stirs precipitation and spends the night.Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids (white sugar, Mel, benzene first propanoic acid or ethyl hydroxybenzoate etc.), make mixture, oral liquid or syrup.
The clinical experiment of embodiment 29 traditional Chinese medicine composition for treating chronic atrophic gastritis
1 data and method
1.1 physical data
1.1.1 object of study 90 routine CAG patients are the patient who accepts for medical treatment in the outpatient service of Gastroenterology dept. of hospital and ward year January in March, 2008 to 2009, male's 41 examples, women's 49 examples, before two groups of patient treatments at aspects such as sex, age, the courses of disease there are no significant difference.
1.1.2 Western medicine diagnose standard reference in May, 2000 Jinggang Mountain " national chronic gastritis seminar common recognition suggestion " formulated.
1.1.3 the standard of tcm diagnosis standard reference " new Chinese medicine clinical research guideline " " the clinical research guideline of new Chinese medicine treatment atrophic gastritis ".
1.1.4 the standard of including in
1. meet the Western medicine diagnose standard of chronic atrophic gastritis, and meet endoscopic diagnosis standard and pathological diagnosis standard simultaneously.
2. meet " Shanghai City disease of tcm conventional treatment " " stomach painful abdominal mass disease " incoordination between the liver and stomach, damp-heat in the spleen and stomach, stomach-Yin deficiency.
3. the age is at 18-65 between one full year of life.
4. receive treatment voluntarily.
1.1.5 exclusion standard
1. merge peptic ulcer, gastric mucosa has severe dysplasia or pathological diagnosis to be suspected to have the person of cancerating.
2. merge serious primary disease such as the heart, brain, liver, kidney and hemopoietic system, the psychotic.
3. gestation or prepare the gravid woman, women breast-feeding their children.
4. allergic constitution maybe may be to the patient of trial drug composition allergy.
5. participating in the patient of other drug clinical trial.
6. meet Shanghai City disease of tcm conventional treatment " stomach painful abdominal mass disease " due to weakness of spleen and stomach.
7. the age is less than 18 years old or greater than 65 years old.
1.2 treatment grouping and method
90 routine CAG patients are divided into one group of 30 example for the treatment of by Chinese herbs, two group of 30 example for the treatment of by Chinese herbs and western medicine group 30 examples at random, treat one group and give Chinese medicine composition one (with reference to embodiment 12 and 25 preparations), sooner or later twice oral, treat two groups and give Chinese medicine composition two (with reference to embodiment 24 and 25 preparations), sooner or later twice oral; Matched group gives western medicine (2 Tid are oral for gefarnate, and folic acid 10mg Tid is oral), and 3 months is a course for the treatment of, and companion HP the infected all adopts international suggested design to give standard dose proton pump inhibitor (PPI)+two kind of antibiotic and eradicates HP.
1.3 observation index
Clinical symptoms, gastroscope and gastric mucosa histopathology change.
1.4 statistical analysis technique
Adopt SPSS for windows 13.0 statistical analysis softwares to add up by enumeration data X 2 test, measurement data T check.
2 results
2.1 treat last as situation
2.1.1 three groups of ages, sex ratio be (seeing Table 1)
Three groups of ordinary circumstances comparisons of table 1 (X ± S)
Annotate: relatively sex, equal not statistically significant of age (P〉0.05) between group.
2.1.2 clinical symptoms compares (seeing Table 2) before three groups of treatments
Clinical symptoms relatively before three groups of treatments of table 2
Annotate: clinical symptoms constitutes and learns check by statistics there are no significant difference (P〉0.05) before three groups of patient treatments, and comparability is arranged.
2.2 the variation of three groups of each observation index in treatment back
2.2.1 traditional Chinese medical science disease integration changes relatively (seeing Table 3) before and after three groups of treatments
Traditional Chinese medical science disease efficacy evaluation (%) before and after three groups of treatments of table 3
Annotate: compare with matched group: * P＜0.01.
As can be seen from Table 3, three groups for the treatment of front and back total effective rates are learned check by statistics, and there were significant differences (P＜0.01), and statistical significance is arranged, and illustrates that the total effective rate of two groups of one group for the treatment of and treatments all is higher than matched group.
2.2.2 the chronic atrophic gastritis curative effect compares (seeing Table 4) before and after three groups of treatments
Chronic atrophic gastritis curative effect (%) before and after three groups of treatments of table 4
Annotate: compare with matched group: * P＜0.05.
As can be seen from Table 4, total effective rate is learned check by statistics before and after three groups of treatments notable difference (P＜0.05), and statistical significance is arranged, and illustrates that the total effective rate of two groups of one group for the treatment of and treatments all is higher than matched group.
2.2.3 the atrophy curative effect compares (seeing Table 5) before and after three groups of treatments
Atrophy curative effect (%) before and after three groups of treatments of table 5
Annotate: compare with matched group: * P＜0.05.
Can find out that from table 5 pathological change of three groups for the treatment of back atrophys relatively has notable difference (P＜0.05).
2.2.4 the inflammation curative effect compares (seeing Table 6) before and after three groups of treatments
Inflammation curative effect (%) before and after three groups of treatments of table 6
Annotate: compare with matched group: * P 0.05.
As can be seen from Table 6, total effective rate is learned the no significant difference of check (P〉0.05) by statistics before and after three groups of treatments, and not statistically significant illustrates that three groups of treatments are all effective, and treats one group and treat two groups and matched group no significant difference.
2.2.5 three groups for the treatment of ideocolon epithelial metaplasia curative effects compare (seeing Table 7)
Three groups of treatments of table 7 ideocolon epithelial metaplasia curative effect (%)
Annotate: compare with matched group: * P＜0.05.
As can be seen from Table 7, total effective rate is learned check by statistics before and after three groups of treatments notable difference (P＜0.05), and statistical significance is arranged, and illustrates that one group for the treatment of and two groups of total effective rates for the treatment of are higher than matched group.
2.2.6 the dysplasia curative effect compares (seeing Table 8) before and after three groups of treatments
Dysplasia curative effect (%) before and after three groups of treatments of table 8
As can be seen from Table 8, because case load is very few, though three groups for the treatment of front and back dysplasia effective percentage all are 100%, do not have statistical significance.
2.2.7 HP infects and treatment situation (seeing Table 9) before and after three groups of treatments
HP changes before and after three groups of treatments of table 9
Annotate: compare with matched group: * P 0.05.
As can be seen from Table 9, three groups have the HP infected patient all to adopt Same Way treatment (two kinds of antibiotic of PPI+), and the HP state is learned check no significant difference (P〉0.05) by statistics before and after three groups of treatments as a result.
3 discuss
Chronic atrophic gastritis (ehronica trophic gastritis, CAG) be with gastric epithelial and body of gland atrophy, the mucosa attenuation, muscular layer of mucosa thickens and with intestinal epithelial metaplasia, atypical hyperplasia is a kind of common digestive system disease of feature, it is one of preceding disease (state) of cancer of gastric cancer, account for gastroscope and examined about 14.2% of case, and the canceration rate of CAG companion's severe intestinal metaplasia and atypical hyperplasia can reach 2.0-13.8%, therefore, active treatment CAG patient, especially with intestinal epithelial metaplasia, the CAG patient of atypical hyperplasia is conducive to reduce the gi system tumor incidence, improves patient's quality of life.
Motherland's medical science thinks that the primary disease etiology and pathogenesis is mainly innate deficiency, disorder of emotion, eating and drinking without temperance, maladjustment in work and rest, six climate exopathogens and reason such as attacks outward and cause weakness of the spleen and stomach.Spleen loses fortuneization, and stomach is received mistake department, and the fortune of receiving is not normal, causes lifting mistake department, and the middle stagnation of QI is stagnant, or middle soil is not flourish, and the venation mistake is foster, causes the generation of primary disease.
Chinese medicine composition of the present invention has invigorating the spleen and regulating the stomach, replenishing YIN and removing heat, and the effect of promoting QI to circulate and dispersing the agglomeration of the pathogens, full side's compatibility has the effect of preventing and treating deficiency-heat type (comprising type of deficiency of stomach yin) CAG.
The present invention studies show that: Chinese medicine composition one of the present invention and Chinese medicine composition two can significantly improve patient's gastric abscess, clinical symptoms such as abdominal distention and belch pantothenic acid, efficacy determination as seen under the mirror, the effective percentage of Chinese medicine composition one and Chinese medicine composition two treatment CAG is respectively 96.15% and 95.83%, the effective percentage of matched group is 67.86%: from tissue pathologies change as seen, the effective percentage that Chinese medicine composition one and Chinese medicine composition two improve the atrophy of CAG is respectively 88.46% and 91.67%, the effective percentage that improves the intestinal epithelial metaplasia of CAG is respectively 81.82% and 80.00%, is better than matched group (P＜0.05).
Its possible mechanism is by invigorating spleen and reinforcing stomach, tonification day after tomorrow makes QI and blood biochemistry active, and taste must be supported, and then disease is to more.Modern pharmacological research thinks that qi-benefiting and spleen-strengthening drug can improve the gastrointestinal blood circulation, increases the blood supply of diseased region, corrects the hypoxic-ischemic of local organization, promotes inflammation to absorb and tissue repair; Regulate immunologic function, increase the reticuloendothelial cell phagocytosis, improve lymhocyte transformation rate, strengthen the gastrointestinal tract mucosa barrier function, thereby block and reverse the process of body of gland atrophy and canceration.On the other hand, the removing dampness detoxifcation is for scheming controlling of this.By removing dampness detoxifcation, dispel virulence factor, improve gastric noxious dampness environment, make the gastric juice abundance, the stomach film must be supported, thereby makes the body of gland of atrophy and the intestinalization that occurs together is improved and eliminates.
The above only is preferred implementation of the present invention; should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the inventive method; can also make some improvement and replenish, these improvement and replenish and also should be considered as protection scope of the present invention.
Claims (8)
1. Chinese medicine composition for the treatment of chronic gastritis, it is characterized in that described Chinese medicine composition is mainly made by following bulk drugs: Radix Codonopsis 30-35 part, Radix Astragali 25-30 part, Rhizoma Atractylodis Macrocephalae (parched with bran) 15-25 part, Fructus Jujubae 30-35 part, Radix Rehmanniae 25-30 part, Radix Angelicae Sinensis 25-30 part, Cortex Moutan 25-30 part, Rhizoma Chuanxiong 25-30 part, Rhizoma Curcumae 25-30 part, Radix Trichosanthis 25-30 part, Herba Taraxaci 20-25 part.
2. Chinese medicine composition according to claim 1, it is characterized in that described Chinese medicine composition is mainly made by following bulk drugs: Radix Codonopsis 33-34 part, Radix Astragali 26-27 part, Rhizoma Atractylodis Macrocephalae (parched with bran) 19-21 part, Fructus Jujubae 33-34 part, Radix Rehmanniae 26-27 part, Radix Angelicae Sinensis 26-27 part, Cortex Moutan 26-27 part, Rhizoma Chuanxiong 26-27 part, Rhizoma Curcumae 26-27 part, Radix Trichosanthis 26-27 part, Herba Taraxaci 23-24 part.
3. Chinese medicine composition according to claim 1, it is characterized in that described Chinese medicine composition is mainly made by following bulk drugs: 33.3 parts of Radix Codonopsis, 26.7 parts of the Radixs Astragali, 20 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 33.3 parts in Fructus Jujubae, 26.7 parts of Radix Rehmanniae, 26.7 parts of Radix Angelicae Sinensis, 26.7 parts of Cortex Moutans, 26.7 parts of Rhizoma Chuanxiongs, 26.7 parts of Rhizoma Curcumae, 26.7 parts of Radix Trichosanthis, 23.3 parts of Herba Taraxacis.
4. Chinese medicine composition for the treatment of chronic gastritis, it is characterized in that described Chinese medicine composition is mainly made by following bulk drugs: Herba Pogostemonis stalk 15-25 part, Caulis Perillae 15-25 part, Rhizoma Atractylodis Macrocephalae (parched with bran) 15-25 part, stir-baked Fructus Aurantii in bran 15-25 part, Semen Vignae Cylindricae KOUREN 5-10 part, Fructus Citri Sarcodactylis 15-25 part, Fructus Mume 5-15 part processed, Rhizoma Zingiberis Recens 10-15 part, Fructus Jujubae 30-35 part, Radix Glycyrrhizae 10-15 part, Radix Astragali 25-30 part, Radix Rehmanniae 25-30 part, Cortex Moutan 25-30 part, Radix Trichosanthis 25-30 part, Herba Taraxaci 20-25 part, Radix Angelicae Sinensis 25-30 part, Rhizoma Chuanxiong 25-30 part, Rhizoma Curcumae 25-30 part, Fructus Lycii 25-30 part, Rhizoma Coptidis 1-4 part, Radix Codonopsis 30-35 part.
5. Chinese medicine composition according to claim 4, it is characterized in that described Chinese medicine composition is mainly made by following bulk drugs: Herba Pogostemonis stalk 17-23 part, Caulis Perillae 17-23 part, Rhizoma Atractylodis Macrocephalae (parched with bran) 17-23 part, stir-baked Fructus Aurantii in bran 17-23 part, Semen Vignae Cylindricae KOUREN 6-7 part, Fructus Citri Sarcodactylis 17-23 part, Fructus Mume 7-13 part processed, Rhizoma Zingiberis Recens 13-14 part, Fructus Jujubae 33-34 part, Radix Glycyrrhizae 13-14 part, Radix Astragali 26-27 part, Radix Rehmanniae 26-27 part, Cortex Moutan 26-27 part, Radix Trichosanthis 26-27 part, Herba Taraxaci 23-24 part, Radix Angelicae Sinensis 26-27 part, Rhizoma Chuanxiong 26-27 part, Rhizoma Curcumae 26-27 part, Fructus Lycii 26-27 part, Rhizoma Coptidis 2-3 part, Radix Codonopsis 33-34 part.
6. Chinese medicine composition according to claim 4, it is characterized in that described Chinese medicine composition is mainly made by following bulk drugs: 20 parts on Herba Pogostemonis stalk, 20 parts of Caulis Perillaes, 20 parts of Rhizoma Atractylodis Macrocephalae (parched with bran), 20 parts of stir-baked Fructus Aurantii in bran, 6.7 parts of Semen Vignae Cylindricae KOUREN, 20 parts of Fructus Citri Sarcodactylis, 10 parts of Fructus Mumes processed, 13.3 parts in Rhizoma Zingiberis Recens, 33.3 parts in Fructus Jujubae, 13.3 parts in Radix Glycyrrhizae, 26.7 parts of the Radixs Astragali, 26.7 parts of Radix Rehmanniae, 26.7 parts of Cortex Moutans, 26.7 parts of Radix Trichosanthis, 23.3 parts of Herba Taraxacis, 26.7 parts of Radix Angelicae Sinensis, 26.7 parts of Rhizoma Chuanxiongs, 26.7 parts of Rhizoma Curcumae, 26.7 parts of Fructus Lycii, 2.3 parts of Rhizoma Coptidis, 33.3 parts of Radix Codonopsis.
7. according to the application of the arbitrary described Chinese medicine composition of claim 1-6 in the medicine of preparation treatment chronic gastritis.
8. application according to claim 7 is characterized in that, described chronic gastritis is chronic atrophic gastritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310084969.7A CN103182059B (en) | 2013-03-18 | 2013-03-18 | Traditional Chinese medicine composition for treating chronic gastritis, and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310084969.7A CN103182059B (en) | 2013-03-18 | 2013-03-18 | Traditional Chinese medicine composition for treating chronic gastritis, and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103182059A true CN103182059A (en) | 2013-07-03 |
| CN103182059B CN103182059B (en) | 2014-10-08 |
Family
ID=48673674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310084969.7A Active CN103182059B (en) | 2013-03-18 | 2013-03-18 | Traditional Chinese medicine composition for treating chronic gastritis, and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103182059B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103520620A (en) * | 2013-10-22 | 2014-01-22 | 刘守梅 | Traditional Chinese medicinal preparation for treating spleen-stomach deficiency type chronic gastritis and preparation method of traditional Chinese medicinal preparation |
| CN103705881A (en) * | 2013-12-13 | 2014-04-09 | 青岛中科菲力工程技术研发有限公司 | Honey pill for treating epigastric pain and preparation method thereof |
| CN103845695A (en) * | 2014-01-29 | 2014-06-11 | 杭州市中医院 | Compound stomach medicine for benefiting qi for activating blood circulation and preparation method thereof |
| CN105381413A (en) * | 2015-12-17 | 2016-03-09 | 济南昊泽环保科技有限公司 | Compound preparation for treating atrophic gastritis |
| CN103845695B (en) * | 2014-01-29 | 2018-08-31 | 杭州市中医院 | A kind of compound stomach medicine of qi and activate blood circulation and preparation method thereof |
| CN115487284A (en) * | 2022-09-30 | 2022-12-20 | 四川省肿瘤医院 | Traditional Chinese medicine composition, traditional Chinese medicine ointment, preparation method of traditional Chinese medicine ointment and application of traditional Chinese medicine ointment |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1094959A (en) * | 1993-05-13 | 1994-11-16 | 山东省医学科学院基础医学研究所 | A kind of Chinese medicine for the treatment of gastropathy |
| CN101396548A (en) * | 2007-09-30 | 2009-04-01 | 杨勤 | Medicine composition for treating chronic gastritis |
-
2013
- 2013-03-18 CN CN201310084969.7A patent/CN103182059B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1094959A (en) * | 1993-05-13 | 1994-11-16 | 山东省医学科学院基础医学研究所 | A kind of Chinese medicine for the treatment of gastropathy |
| CN101396548A (en) * | 2007-09-30 | 2009-04-01 | 杨勤 | Medicine composition for treating chronic gastritis |
Non-Patent Citations (2)
| Title |
|---|
| 周秉舵: "朱生樑辨治慢性萎缩性胃炎经验", 《上海中医药杂志》 * |
| 王萍等: "中医辨证治疗慢性萎缩性胃炎配伍用药规律分析", 《中华中医药学刊》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103520620A (en) * | 2013-10-22 | 2014-01-22 | 刘守梅 | Traditional Chinese medicinal preparation for treating spleen-stomach deficiency type chronic gastritis and preparation method of traditional Chinese medicinal preparation |
| CN103520620B (en) * | 2013-10-22 | 2015-09-30 | 刘守梅 | A kind of Chinese medicine preparation and preparation method for the treatment of due to weakness of spleen and stomach chronic gastritis |
| CN103705881A (en) * | 2013-12-13 | 2014-04-09 | 青岛中科菲力工程技术研发有限公司 | Honey pill for treating epigastric pain and preparation method thereof |
| CN103845695A (en) * | 2014-01-29 | 2014-06-11 | 杭州市中医院 | Compound stomach medicine for benefiting qi for activating blood circulation and preparation method thereof |
| CN103845695B (en) * | 2014-01-29 | 2018-08-31 | 杭州市中医院 | A kind of compound stomach medicine of qi and activate blood circulation and preparation method thereof |
| CN105381413A (en) * | 2015-12-17 | 2016-03-09 | 济南昊泽环保科技有限公司 | Compound preparation for treating atrophic gastritis |
| CN115487284A (en) * | 2022-09-30 | 2022-12-20 | 四川省肿瘤医院 | Traditional Chinese medicine composition, traditional Chinese medicine ointment, preparation method of traditional Chinese medicine ointment and application of traditional Chinese medicine ointment |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103182059B (en) | 2014-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103751739A (en) | Traditional Chinese medicine composition for treating chronic gastritis, application of composition in preparation of medicine for treating chronic gastritis, and preparation method of composition | |
| CN103182059B (en) | Traditional Chinese medicine composition for treating chronic gastritis, and application thereof | |
| CN102488743B (en) | Chinese traditional medicine composition, preparation method thereof and Chinese traditional medicine preparation | |
| CN100548354C (en) | A kind of oral liquid for the treatment of nephropathy | |
| CN103110816B (en) | Chinese herba preparation for treating chronic ulcerative colitis | |
| CN110193050A (en) | Traditional Chinese medicine composition for preventing recurrence and metastasis of digestive tract tumor and preparation method thereof | |
| CN101804189B (en) | Drug for treating primary dysmenorrhea | |
| CN105832991A (en) | Traditional Chinese medicine composition for treating gastritis | |
| CN101693084B (en) | Medical composition for treating epigastric pain yin deficiency syndrome and preparation method thereof | |
| CN104000938B (en) | Traditional Chinese medicine composition for treating IgA nephropathy and application thereof | |
| CN1903347A (en) | Medicine composition for treating alimentary canal diseases, prepn. method and application thereof | |
| CN105641419A (en) | Traditional Chinese medicine composition for treating Yin deficiency type cough caused by lung cancer | |
| CN101502597B (en) | Medicament for treating stomachache and preparation method thereof | |
| CN104225016A (en) | Drug composition for treating spleen and stomach deficiency type chronic atrophic gastritis | |
| CN107952020A (en) | One kind breeds ball | |
| CN102488804A (en) | Traditional Chinese medicine for treating cirrhosis | |
| CN103191345B (en) | Postoperative drug for chronic peptic ulcer and esophagitis syndrome | |
| CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method | |
| CN101693096A (en) | Medicament for treating liver cancer and preparation method thereof | |
| CN105232609A (en) | Traditional Chinese medicine combination treating functional dyspepsia | |
| CN105214067A (en) | A kind of medicine for the treatment of cancer patients diarrhoea | |
| CN104547923A (en) | Traditional Chinese medicine composition for treating gouty nephropathy and application thereof | |
| CN105617197A (en) | Traditional Chinese medicine composition for treating chronic renal failure of dogs as well as preparation method and application of traditional Chinese medicine composition | |
| CN105267656A (en) | Traditional Chinese medicine composition for treating constipation occurring after malignant neoplasm chemotherapy | |
| CN105106633B (en) | A kind of Chinese medicinal capsule for treating gastric ulcer and its complication |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |